Clinical trial of human (allogeneic) induced pluripotent stem cell-derived cardiomyocyte sheet for severe cardiomyopathy

General Information

Description The study is in two parts, Part 1 (safety cohort) is to ensure that the vaccine can be given safely and to see if there are any initial signs of how it works in the body by performing tests on blood and tissue samples. Patients with advanced NSCLC will be asked to participate in Part 1.
Clinical trials phase Phases 1/2
Start date (estimated) 2018-06-11
End date (estimated) 2022-06-30
Clinical feature
Label ischemic cardiomyopathy
Description Ischemic cardiomyopathy is a cardiomyopathy in which a weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease being the most common cause.

Administrative Information

ICTRP weblink
Other study identifiers
Name UMIN000032989
Description UMIN Clinical Trials Registry´╝łUMIN-CTR
Name PA8170002
Source weblink
Regulatory body approval
Public contact
Public email
First name Shigeru
Last name Miyagawa
Phone +81 (0)6-6879-3154
Street 2-2, Yamadaoka, Suita city, Osaka
Postcode 565-0871
City Osaka
Sponsors Osaka University Hospital

Cell Line


Recruitment Status Not yet recruiting
Comment recruitment status Preinitiation [Pendging]
Estimated number of participants 3